22:39 , Jun 16, 2017 |  BC Extra  |  Clinical News

Merck team ties PD-L2 to immunotherapy response

In a paper published in Clinical Cancer Research, researchers at Merck & Co. Inc. (NYSE:MRK) showed programmed cell death 1 ligand 2 (PD-L2; PDCD1LG2; B7-DC) could predict patient response to PD-1 checkpoint inhibitors including Keytruda...
07:00 , Sep 1, 2016 |  BC Innovations  |  Translation in Brief

Malaria's checkpoint sister

With all eyes on the interaction of PD-1 with its ligand PD-L1 in immuno-oncology, an Australian group has highlighted the therapeutic potential of a second ligand, PD-L2, which could be exploited for driving immunity against...
07:00 , May 29, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Programmed cell death 1 ligand 2 (PDCD1LG2; B7-DC; PD-L2); repulsive guidance molecule family member b (RGMB) ...
08:00 , Jan 13, 2014 |  BioCentury  |  Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for growth....
07:00 , Sep 9, 2013 |  BioCentury  |  Product Development

Checkpoint complementarity

The acquisition of Amplimmune Inc. adds a new set of immune checkpoint targets to MedImmune LLC's cancer portfolio, giving it more potential combinations to test in cancer. The AstraZeneca plc unit now has four disclosed checkpoint...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Amplimmune, AstraZeneca deal

AstraZeneca's MedImmune LLC biologics unit will acquire cancer immunotherapy company Amplimmune for $225 million up front and up to $275 million in development milestones. MedImmune will gain Amplimmune's pipeline of immunomodulators, including Amplimmune's most...
00:07 , Aug 27, 2013 |  BC Extra  |  Company News

MedImmune to acquire Amplimmune

The MedImmune LLC biologics unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) will acquire cancer immunotherapy company Amplimmune Inc. (Rockville, Md.) for $225 million up front and up to $275 million in milestones. MedImmune will gain Amplimmune's...
07:00 , Jun 18, 2012 |  BioCentury  |  Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
07:00 , Aug 19, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious disease Viral infection PD-1 receptor (PDCD1; PD-1; CD279); programmed cell death 1 ligand 1 (CD274 molecule; PD-L1;...
07:00 , Aug 9, 2010 |  BioCentury  |  Finance

Amplified Opportunity

Amplimmune Inc. has made the most of an initial $20 million round of financing, as the company has made progress with a pair of preclinical fusion proteins, the more advanced of which was snapped up...